This–together with the finding that BAP1 mutation rates were significantly higher, and BAP1 mutations almost exclusively present, in HBV RNA negative tumors–suggests that BAP1 mutant HCC could represent an HCC subtype characterized by lack of HBV activity in tumor and improved outcomes. This evidence concerns the gene BAP1 and hepatocellular carcinoma.